Citius Oncology, Inc. Diluted Shares Outstanding (Weighted Average)
Citius Oncology, Inc. (CTOR) reported Diluted Shares Outstanding (Weighted Average) of 107.89 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding · last filed 2026-08-14
- Citius Oncology, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2026-06-30 was 107.89M shares, a 50.79% increase year-over-year.
- Citius Oncology, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2026-03-31 was 100.03M shares, a 39.80% increase year-over-year.
- Citius Oncology, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2025-12-31 was 87.46M shares, a 22.24% increase year-over-year.
- Citius Oncology, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2025-09-30 was 78.41M shares, a 12.48% increase year-over-year.
- Citius Oncology, Inc. weighted average number of shares outstanding, diluted for fiscal 2025 was 73.27M shares, a 7.66% increase from fiscal 2024.
- Citius Oncology, Inc. weighted average number of shares outstanding, diluted for fiscal 2024 was 68.05M shares.
- Citius Oncology, Inc. weighted average number of shares outstanding, diluted for fiscal 2023 was 6.60M shares.
- Citius Oncology, Inc. weighted average number of shares outstanding, diluted for fiscal 2023 was 67.50M shares.
| Period end | Weighted Average Number of Shares Outstanding, Diluted 3 month | Weighted Average Number of Shares Outstanding, Diluted 3 month as first filed | Weighted Average Number of Shares Outstanding, Diluted 6 month | Weighted Average Number of Shares Outstanding, Diluted 9 month | Weighted Average Number of Shares Outstanding, Diluted 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 107.89M shares 10-Q · filed 2026-08-14 | 103.96M shares derived: average of 2 quarters · filed 2026-08-14 | 98.41M shares 10-Q · filed 2026-08-14 | 93.45M shares derived: average of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | 100.03M shares 10-Q · filed 2026-05-15 | 93.66M shares 10-Q · filed 2026-05-15 | 88.63M shares derived: average of 3 quarters · filed 2026-05-15 | 84.36M shares derived: average of 4 quarters · filed 2026-08-14 | |
| 2025-12-31 | 87.46M shares 10-Q · filed 2026-02-13 | 82.94M shares derived: average of 2 quarters · filed 2026-02-13 | 79.14M shares derived: average of 3 quarters · filed 2026-08-14 | 77.25M shares derived: average of 4 quarters · filed 2026-08-14 | |
| 2025-09-30 | 78.41M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-23 | 74.98M shares derived: average of 2 quarters · filed 2026-08-14 | 73.84M shares derived: average of 3 quarters · filed 2026-08-14 | 73.27M shares 10-K · filed 2025-12-23 | |
| 2025-06-30 | 71.55M shares 10-Q · filed 2026-08-14 | 71.55M shares derived: average of 2 quarters · filed 2026-08-14 | 71.55M shares 10-Q · filed 2026-08-14 | 71.09M shares derived: average of 4 quarters · filed 2026-08-14 | |
| 2025-03-31 | 71.55M shares 10-Q · filed 2026-05-15 | 71.55M shares 10-Q · filed 2026-05-15 | 70.94M shares derived: average of 3 quarters · filed 2026-05-15 | 70.08M shares derived: average of 4 quarters · filed 2026-05-15 | |
| 2024-12-31 | 71.55M shares 10-Q · filed 2026-02-13 | 70.63M shares derived: average of 2 quarters · filed 2026-02-13 | 69.59M shares derived: average of 3 quarters · filed 2026-02-13 | 69.07M shares derived: average of 4 quarters · filed 2026-02-13 | |
| 2024-09-30 | 69.71M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-23 | 68.61M shares derived: average of 2 quarters · filed 2025-12-23 | 68.24M shares derived: average of 3 quarters · filed 2025-12-23 | 68.05M shares 10-K · filed 2025-12-23 | |
| 2024-06-30 | 67.50M shares 10-Q · filed 2025-08-12 | 4.31M shares 10-Q · filed 2024-08-09 | 4.53M shares 10-Q · filed 2024-08-09 | 67.50M shares 10-Q · filed 2025-08-12 | 52.27M shares derived: average of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | 67.50M shares 10-Q · filed 2025-05-14 | 4.74M shares 10-Q · filed 2024-05-20 | 67.50M shares 10-Q · filed 2025-05-14 | 47.20M shares derived: average of 3 quarters · filed 2025-05-14 | 37.05M shares derived: average of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | 67.50M shares 10-Q · filed 2025-02-14 | 37.05M shares derived: average of 2 quarters · filed 2025-02-14 | 26.90M shares derived: average of 3 quarters · filed 2025-02-14 | 6.60M shares 10-K · filed 2024-04-16 | |
| 2023-09-30 | 6.60M shares 10-Q · filed 2023-11-20 | 6.60M shares derived: average of 2 quarters · filed 2024-08-09 | 6.60M shares 10-Q · filed 2023-11-20 | 67.50M shares 10-K · filed 2024-12-27 | |
| 2023-06-30 | 6.60M shares 10-Q · filed 2024-08-09 | 6.60M shares 10-Q · filed 2024-08-09 | 4.69M shares derived: average of 3 quarters · filed 2024-08-09 | 3.89M shares derived: average of 4 quarters · filed 2024-08-09 | |
| 2023-03-31 | 6.60M shares 10-Q · filed 2024-05-20 | 2.42M shares 10-Q · filed 2023-05-15 | 3.73M shares derived: average of 2 quarters · filed 2024-05-20 | 2.99M shares derived: average of 3 quarters · filed 2024-05-20 | 2.62M shares derived: average of 4 quarters · filed 2024-05-20 |
| 2022-12-31 | 867.03K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16 | 1.18M shares derived: average of 2 quarters · filed 2024-04-16 | 1.29M shares derived: average of 3 quarters · filed 2024-04-16 | 1.34M shares 10-K · filed 2024-04-16 | |
| 2022-09-30 | 1.50M shares 10-Q · filed 2023-11-20 | 1.50M shares derived: average of 2 quarters · filed 2023-11-20 | 1.50M shares 10-Q · filed 2023-11-20 | ||
| 2022-06-30 | 1.50M shares 10-Q · filed 2023-08-16 | 1.50M shares 10-Q · filed 2023-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |